SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

A sharp price correction pushed Bitcoin toward key support around $60,000, fueling intense debate as some in the community declare the 'ponzi' over while others view it as a generational buying opportunity amidst a flush of 'weak hands' and speculative institutional accumulation.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending after its Q4 earnings, with a substantial forecast of $200 billion in 2026 capital expenditures for AI infrastructure triggering a sell-off, as the community debates whether the market is overreacting to future growth investments despite solid AWS performance.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending amidst a significant crypto market downturn, driven by Bitcoin's sharp pullback and concerns over regulatory hurdles, leading to a polarized community debating capitulation versus a generational buying opportunity.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is a major talking point after its recent earnings report revealed significant misses on revenue and EPS, driving a sharp sell-off. While critics point to current losses and a slower AI revenue ramp, supporters emphasize the substantial funding secured for its AI infrastructure pivot and expanding power capacity, creating a strong divergence in community sentiment.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Holdings Inc

Ondas Holdings Inc. is trending following a significant market-wide sell-off and Bitcoin's plummeting value, with a controversial short report also fueling discussion. Despite widespread frustration over deep losses, many investors are seizing the opportunity to buy, confident in the company's substantial cash reserves and long-term prospects within the defense and drone technology sector.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is experiencing extreme volatility and heavy discussion following its Q4 earnings, which revealed a substantial operating loss tied to the recent significant dip in the broader crypto market. The community is sharply divided between those predicting further collapse due to its leveraged Bitcoin strategy and those holding firm, citing management's long-term confidence in Bitcoin's recovery.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending following the launch of a new, cheaper compounded weight-loss pill and expanded cancer screening services, sparking both bullish anticipation for market share growth and intense community debate amidst immediate legal threat warnings from a major pharmaceutical company and increased regulatory scrutiny over its offerings.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amidst a significant sell-off, largely influenced by cryptocurrency market volatility and its perceived strong correlation to Bitcoin's price, with the community sharply divided on whether the stock is profoundly oversold. Many are keenly anticipating upcoming earnings to potentially stabilize the stock, while others express concerns over further declines and market "manipulation."

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending amid a sharp crypto market flash crash and massive liquidations, polarizing the community between those panic selling and others viewing it as a generational buying opportunity, all while regulatory uncertainty adds to the volatile sentiment.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending amid a broad tech sell-off, sparked by concerns over massive AI capital expenditures from major companies like Amazon and a significant crypto market decline. The community is actively debating whether current tech valuations are justified and if the market is undergoing a crucial reset or heading into a deeper correction.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

<ul class="summary-bullets"><li>The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial.</li><li>The proposal includes amending the ongoing VERSATILE-003 Phase 3 study to add progression-free survival as an earlier primary endpoint, potentially allowing for an earlier submission.</li><li>Retail traders on Stocktwits flooded discussions with optimism, calling the stock “too cheap” and speculating that the FDA could grant early approval to give patients faster access to the therapy.</li></ul>Shares of PDS Biotechnology logged their best session in more than two months after the late-stage immunotherapy company said it has requested a meeting with the U.S. Food and Drug Administration to discuss an expedited approval pathway for PDS0101, its lead candidate in HPV16-positive head and neck cancer.<h2 class="st-heading-2">FDA Meeting Request</h2>The company said the request follows a review of the final VERSATILE-002 trial data and a proposal to amend the ongoing VERSATILE-003 Phase 3 study. The amendment would reduce the number of patients while maintaining statistical power and add progression-free survival (PFS) as an earlier primary endpoint, alongside median overall survival (mOS).If the PFS endpoint is met, it could allow for an accelerated approval submission to the FDA. While the amendment is under review, the VERSATILE-003 trial will be temporarily paused, though treatment for currently enrolled patients will continue.<h2 class="st-heading-2">Almost 40 Months Of Median Survival</h2>CEO Frank Bedu-Addo said the final survival results from VERSATILE-002 were “very exciting,” noting that it was the first trial in the recurrent or metastatic head and neck cancer population to show a median overall survival of almost 40 months. He added that seeking to include PFS as an earlier primary endpoint could shorten the trial duration.Chief Medical Officer Kirk Shepard said the company’s goal is to pursue the fastest and most cost-effective regulatory path for approval and to provide a non-chemotherapy option for patients who currently lack effective therapies.<h2 class="st-heading-2">Trial Background</h2>VERSATILE-002 is an open-label, multi-center Phase 2 trial evaluating the safety and efficacy of PDS0101, an HPV16-targeted immunotherapy, in combination with pembrolizumab for unresectable, recurrent or metastatic HPV16-positive head and neck cancer.On Stocktwits, retail sentiment for PDS Biotechnology was ‘extremely bullish’ amid a 2,333% surge in 24-hour message volume.<h2 class="st-heading-2">Stocktwits Bulls Bet On Early FDA Nod</h2>One user said the news was “very good” and that the stock looked “way too cheap,” suggesting they were watching for more upside.<stembedurl>https://stocktwits.com/makedatbread88/message/634249334</stembedurl>Another user speculated that the FDA might allow an early approval if PDS agreed to continue trials at the same time, calling it a move that could give very sick head and neck cancer patients access to a potentially life-saving therapy.<stembedurl>https://stocktwits.com/Stockman824/message/634214470</stembedurl><a href="https://stocktwits.com/symbol/PDSB">PDS Biotechnology’s stock</a> has declined 38% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

PDS Biotechnology’s stock (PDSB) has declined 38% so far in 2025. | Image source: Getty Images

PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval

The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial.

Equity

<ul class="summary-bullets"><li>Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids.</li><li>Non-GAAP earnings rose to $2.61 per share, with operating margins improving despite restructuring and impairment charges.</li><li>Retail traders on Stocktwits turned bullish, setting upside targets between $170 and $200 for the stock.</li></ul>Shares of Align Technology rose about 16% in after-hours trading on Wednesday after the Invisalign maker reported third-quarter (Q3) revenue above its own forecast and showed improving momentum in clear aligners for teens and kids.<h2 class="st-heading-2">Results Beat Company Outlook</h2>Align reported Q3 revenue of $995.7 million, up 1.8% year over year and above its guidance range of $965 million to $985 million, though down 1.7% from the prior quarter as the company had flagged. Currency helped, adding about $15.6 million year on year.Clear Aligner revenue was $805.8 million, up 2.4% from a year earlier and flat sequentially. Total clear aligner volume rose 4.9% to 647,800 cases, with the biggest tailwind from younger patients.Treatments for teens and kids jumped 8.3% year over year and 14.7% from Q2 to 256,000 cases, helped by more doctors submitting cases and continued adoption of Invisalign First.The Imaging Systems and CAD/CAM business, which includes iTero scanners, brought in $189.9 million, down 0.6% year over year and 8.6% sequentially, which the company said was normal Q3 capital-equipment seasonality.<h2 class="st-heading-2">Profitability&nbsp;</h2>GAAP operating income was $96.3 million for an operating margin of 9.7%, lower than last year, mainly because the quarter included $88.3 million of restructuring, impairment and accelerated depreciation charges. On a non-GAAP basis, operating margin improved to 23.9%.Net income fell to $56.8 million, or $0.78 per share, from $1.55 a year earlier, largely because of those one-time charges. Non-GAAP EPS was $2.61, up from $2.35.Align ended the quarter with $1 billion in cash and cash equivalents, up from $901 million in the second quarter (Q2).<h2 class="st-heading-2">Outlook</h2>For the fourth quarter (Q4), Align expects revenue of $1.025 billion to $1.045 billion, with clear aligner volume, ASP and systems revenue all seen improving sequentially, and non-GAAP operating margin around 26%.&nbsp;For full-year 2025, the company still expects clear aligner volume to grow in the mid-single digits and revenue to be flat to slightly higher than 2024, reflecting a mixed dental market, especially in North America.<h2 class="st-heading-2">Stocktwits Users Cheer Align’s Strong Quarter</h2>On Stocktwits, retail sentiment for Align was ‘bullish’ amid ‘extremely high’ message volume.One user said Align remains the clear market leader after the quarter and that they were bullish on the stock getting back above $170 by year-end, with a price target of $200 by the first quarter of 2026.&nbsp;<stembedurl>https://stocktwits.com/durocali/message/634224575</stembedurl>Another user said the print was a big beat and flagged $155 as the level to watch on the upside, noting there were still higher gaps to be filled.<stembedurl>https://stocktwits.com/SpudZone/message/634224376</stembedurl><a href="https://stocktwits.com/symbol/ALGN">Align’s stock</a> has declined 37% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Align Technology logo is displayed on a smartphone with a S&P index website background. (Photo Illustration by Alvin Chan/SOPA Images/LightRocket via Getty Images)

Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026

Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids.

Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus

Shares of PDS Biotechnology Corporation (PDSB) drew investor attention on Thursday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/132-2025-news/980-iotecheportsullear2024inancialesultsandr20250327">reported</a> better-than-feared losses for 2024.PDS Biotechnology reported a loss per share of $1.03 for the year, narrower than the $1.39 reported for 2023 and better than an analyst estimate of $1.11, according to FinChat data.Net loss narrowed to $37.61 million in 2024 compared to $42.94 million in the prior year.The reduced losses, the company said, were primarily due to a decrease in operating expenses.Research and development expenses fell during the year to $22.6 million from $27.8 million a year ago, owing to reduced clinical costs, personnel costs, and professional fees.The company ended the year with a cash balance of $41.7 million.Last month, PDS Biotechnology announced an up to $22 million registered direct offering. The company said the securities purchase agreements with new and existing healthcare-focused institutional investors included $11 million of upfront gross proceeds.It also included up to an additional $11 million of aggregate gross proceeds upon cash exercise in full of warrants issued to the investors.PDS is a late-stage immunotherapy company developing investigational products designed to stimulate and enhance targeted T cell responses against cancers.Earlier this month, the company said that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to evaluate a combination of its investigational immunotherapy candidate Versamune MUC1 with a novel investigational tumor-targeting Interleukin 12 to treat colorectal carcinoma in certain patients who failed previous treatment.On Stocktwits, the retail investor sentiment about PDS Biotechnology dropped further into the ‘bearish’ territory (32/100), while message volume remained at the ‘extremely low’ level over the past 24 hours.<figure class="image"><img style="aspect-ratio:647/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_at_12_26_56_PM_png_6c503f4d3f.webp" alt="PDSB's Sentiment Meter and Message Volume as of 12:27 p.m. ET on March 27, 2025 | Source: Stocktwits" width="647" height="151"><figcaption>PDSB's Sentiment Meter and Message Volume as of 12:27 p.m. ET on March 27, 2025 | Source: Stocktwits</figcaption></figure>After the company released its earnings report, HC Wainwright analyst Joseph Pantginis lowered the firm’s price target to $13 from $21 while keeping a ‘Buy’ rating on the shares.A Stocktwits user, however, expressed optimism on the company.<stembedurl>https://stocktwits.com/AyR15/message/609402462</stembedurl>Another user opined that the results were “not as bad as predicted.”<stembedurl>https://stocktwits.com/Mr_Charlie/message/609407057</stembedurl><a href="https://stocktwits.com/symbol/PDSB">PDSB shares</a> have lost over 25% this year and over 65% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/toncoin-gains-outpace-bitcoin-ethereum-after-musk-grok-ai-goes-beyond-x-to-telegram/chJ2BLTRbEJ">Toncoin Gains Outpace Bitcoin, Ethereum After Musk’s Grok AI Goes Beyond X To Telegram – Retail’s Divided</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish

The company said the reduced losses were primarily due to decreased operating expenses.  

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.20	--	--	N/A
Q3 '25	-$0.20	-$0.19	3.39%	BEAT
Q2 '25	-$0.23	-$0.21	10.00%	BEAT
Q1 '25	-$0.25	-$0.21	14.86%	BEAT
Q4 '24	-$0.28	-$0.21	24.10%	BEAT

PDSB
PDS Biotechnology Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest PDSB News

PDSBPDS Biotechnology Corporation